TACTIC-R [COVID-19)] [UPH]
Research type
Research Study
Full title
Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)
IRAS ID
282213
Contact name
Frances Hall
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust
Eudract number
2020-001354-22
ISRCTN Number
ISRCTN11188345
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Several medicines for patients with autoimmune disease (where your immune system mistakenly attacks your body) can be used to prevent overactivation of the immune response (the body’s defence against foreign invaders) in severe COVID-related disease. This study (TACTIC-R) plans to treat patients at an early stage in the disease where the patient is experiencing early infection and starting to show mild lung complications. The purpose is to prevent organ damage and reduce the need to transfer to the Intensive Care Unit and the need for artificial ventilation. Patients will receive one of 3 treatments: baricitinib for 14 days plus normal hospital treatment; ravulizumab single dose plus normal hospital treatment; normal hospital treatment alone. Patients will be followed up after 28 days and 3 months and will undergo blood testing as part of the routine care. The aim of this trial is to identify drugs that can reduce the number of COVID-19 patients that need to be admitted to the Intensive Care Unit.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
20/EE/0135
Date of REC Opinion
6 May 2020
REC opinion
Further Information Favourable Opinion